Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) Receives $4.00 Average Price Target from Analysts

Shares of Mereo BioPharma Group plc – Sponsored ADR (NASDAQ:MREO) have received a consensus recommendation of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat reports. One investment analyst has rated the stock with a sell recommendation, three have issued a hold recommendation and four have assigned a buy recommendation to the company. The average 12-month price target among brokers that have issued ratings on the stock in the last year is $4.00.

MREO has been the subject of several recent research reports. Cantor Fitzgerald reiterated an “overweight” rating on shares of Mereo BioPharma Group in a research report on Monday, December 29th. Robert W. Baird set a $1.00 price objective on Mereo BioPharma Group in a research note on Monday, December 29th. Needham & Company LLC cut their target price on Mereo BioPharma Group from $5.00 to $3.00 and set a “buy” rating on the stock in a research report on Tuesday, January 13th. Wall Street Zen lowered Mereo BioPharma Group from a “hold” rating to a “sell” rating in a report on Saturday, January 3rd. Finally, BTIG Research restated a “buy” rating and issued a $1.00 price target on shares of Mereo BioPharma Group in a research report on Friday, January 16th.

Hedge Funds Weigh In On Mereo BioPharma Group

Several hedge funds have recently added to or reduced their stakes in the company. Frazier Life Sciences Management L.P. boosted its holdings in Mereo BioPharma Group by 20.7% during the 2nd quarter. Frazier Life Sciences Management L.P. now owns 9,440,112 shares of the company’s stock valued at $25,583,000 after acquiring an additional 1,620,249 shares during the period. Aberdeen Group plc lifted its position in shares of Mereo BioPharma Group by 38.4% during the second quarter. Aberdeen Group plc now owns 3,028,872 shares of the company’s stock worth $8,208,000 after purchasing an additional 840,518 shares during the last quarter. Baader Bank Aktiengesellschaft purchased a new stake in shares of Mereo BioPharma Group during the fourth quarter valued at $54,000. Forefront Analytics LLC boosted its stake in shares of Mereo BioPharma Group by 73.4% during the third quarter. Forefront Analytics LLC now owns 33,180 shares of the company’s stock valued at $68,000 after purchasing an additional 14,042 shares during the period. Finally, Clearline Capital LP grew its holdings in shares of Mereo BioPharma Group by 6.0% in the third quarter. Clearline Capital LP now owns 3,834,163 shares of the company’s stock worth $7,898,000 after purchasing an additional 216,000 shares during the last quarter. 62.83% of the stock is currently owned by institutional investors.

Mereo BioPharma Group Stock Up 13.2%

Mereo BioPharma Group stock opened at $0.42 on Wednesday. Mereo BioPharma Group has a 52-week low of $0.20 and a 52-week high of $3.17. The firm’s fifty day moving average is $1.14 and its 200 day moving average is $1.58. The company has a market cap of $67.55 million, a price-to-earnings ratio of -7.08 and a beta of 0.37.

Mereo BioPharma Group (NASDAQ:MREO) last posted its earnings results on Monday, November 10th. The company reported ($0.01) earnings per share for the quarter. On average, equities research analysts anticipate that Mereo BioPharma Group will post -0.03 earnings per share for the current fiscal year.

Key Mereo BioPharma Group News

Here are the key news stories impacting Mereo BioPharma Group this week:

• Negative Sentiment: Bronstein, Gewirtz & Grossman says a class action was filed against Mereo and certain officers seeking damages under federal securities laws for purchases during the stated class period. Bronstein, Gewirtz & Grossman Release
• Negative Sentiment: Several national firms (Faruqi & Faruqi, Rosen, Bragar Eagel & Squire, Levi & Korsinsky, Robbins LLP, Berger Montague, Schall, Holzer & Holzer and others) have announced investigations or filed complaints, increasing probability of consolidated litigation and competing lead‑plaintiff motions. Many note the same class period and encourage investor contact. Faruqi & Faruqi Release
• Negative Sentiment: At least one alert (Holzer & Holzer) highlights specific allegations that Mereo concealed or misrepresented data regarding setrusumab’s ability to achieve statistical significance in its ORBIT and COSMIC trials — an allegation that, if central to the complaint, targets the core biotech value driver. Holzer & Holzer Release
• Negative Sentiment: Practical investor actions: the filings set an April 6, 2026 deadline to seek lead‑plaintiff status; investors who bought ADS during the class period are being solicited to join claims. This increases the chance of formal discovery and public scrutiny of Mereo’s trial communications. DJS Law Group Notice

Mereo BioPharma Group Company Profile

Mereo BioPharma Group plc is a clinical‐stage biopharmaceutical company focused on developing novel therapies for rare diseases, oncology and severe respiratory conditions. The company pursues an asset‐centric model, in which it in-licenses or acquires clinical-stage small molecules and monoclonal antibodies with established safety profiles. By concentrating resources on a select number of programs, Mereo aims to accelerate proof-of-concept studies and maximize the potential value of each therapeutic candidate.

Mereo’s pipeline includes investigational therapies for skeletal disorders, such as setrusumab (BPS-804) for osteogenesis imperfecta, and treatments for acute and chronic respiratory diseases.